Attached files

file filename
EX-99.1 - PRESS RELEASE - Pharma-Bio Serv, Inc.pbsv_ex991.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  December 1, 2014
 
Pharma-Bio Serv, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
0-50956
20-0653570
(Commission File Number)
(I.R.S. Employer Identification No.)

6 Road 696, Dorado, Puerto Rico
00646
(Address of Principal Executive Offices)
(Zip Code)

(787) 278-2709
(Registrant’s Telephone Number, Including Area Code)

 
 
(Former Name or Former Address, if Changed Since Last Report)

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 
 
 
 
Item 8.01.
Other Events.
 
On December 1, 2014, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing that it had retained T.R. Winston & Company in order to assist the Company in enhancing its growth strategy through business development, and mergers and acquisitions.  A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01.
Financial Statements and Exhibits.
 

     
Exhibit No.
Description
99.1
Press release, dated December 1, 2014.
 
 
 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
  PHARMA-BIO SERV, INC.  
       
December 1, 2014
By:
/s/ Pedro J. Lasanta  
    Pedro J. Lasanta  
    Chief Financial Officer  
       
 
 
 
 

 
 
EXHIBIT INDEX
 


                     
Exhibit No.
Description
99.1
Press release, dated December 1, 2014.